Citi analyst Yigal Nochomovitz lowered the firm’s price target on Atara Biotherapeutics to $1.40 from $2 and keeps a Sell rating on the shares. The analyst updated the company’s model post the Q2 results.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on ATRA: